Identification of novel ALK2 inhibitors and their effect on cancer cells

Area of Science:

• Molecular Biology
• Cell Signaling
• Cancer Research

Background:

• Bone morphogenetic protein 9 (BMP9), a TGF-β superfamily member, regulates glucose homeostasis and neuronal differentiation.
• BMP9 signaling involves Smad1/5 phosphorylation via activin receptor-like kinases (ALK1 and ALK2).
• Aberrant ALK2 expression is implicated in various diseases, and BMP9 contributes to tumorigenesis.

Purpose of the Study:

• To investigate the role of BMP9-ALK2 signaling in cancer cell proliferation.
• To identify and characterize specific inhibitors of ALK2 signaling in cancer cells.

Main Methods:

• Utilized TF-1 cells, dependent on GM-CSF for proliferation.
• Assessed BMP9-induced proliferation in TF-1 cells lacking GM-CSF.
• Employed high-throughput screening (HTS) to identify ALK2 inhibitors.
• Evaluated inhibitor potency (IC50) and specificity compared to LDN193189.
• Conducted cell-based assays to measure inhibition of proliferation and migration.

Main Results:

• BMP9 promoted TF-1 cell proliferation independently of GM-CSF.
• Overexpression of ALK2 in TF-1 cells led to Smad1/5 autophosphorylation and increased cell growth.
• Identified two potent and specific ALK2 inhibitors, KRC203 (IC50=0.9 nM) and KRC360 (IC50=0.3 nM).
• KRC203 and KRC360 effectively inhibited BMP9/ALK2-induced cancer cell proliferation and migration.

Conclusions:

• BMP9-ALK2 signaling drives cancer cell proliferation and migration.
• KRC203 and KRC360 are potent and specific ALK2 inhibitors.
• These compounds show promise for treating cancers and other diseases associated with abnormal ALK2 or BMP9 signaling.